CHINA PHARMA HOLDINGS, INC. (CPHI) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CPHI currently has 40.5M outstanding shares. with significant dilution risk as 77.2M authorized shares could dilute existing holders by 190.5%. The company has significantly diluted shareholders by 849.67% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 40.5M shares outstanding |
41M | 77M |
| Apr 01, 2026 |
10-K filing | 40.5M shares outstanding |
41M | 77M |
| Dec 23, 2025 |
8-K filing: China Pharma Holdings, Inc. subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement with Juan Zhang to acquire an Invention Patent for $9.8 million, paid in the form of common stock at $1.40 per share. ($9.8M proceeds) |
5M | 110M |
| Nov 12, 2025 |
10-Q filing | 5.0M shares outstanding |
5M | 110M |
| Aug 14, 2025 |
10-Q filing | 3.3M shares outstanding |
3.3M | 110M |
| May 14, 2025 |
10-Q filing | 3.3M shares outstanding |
3.3M | 110M |
| Mar 31, 2025 |
10-K filing | 32.6M shares outstanding |
33M | 85M |
| Nov 13, 2024 |
10-Q filing | 19.3M shares outstanding |
19M | 98M |
| Aug 14, 2024 |
10-Q filing | 16.1M shares outstanding |
16M | 100M |
| May 15, 2024 |
10-Q filing | 15.9M shares outstanding |
16M | 100M |
| Apr 01, 2024 |
10-K filing | 14.8M shares outstanding |
15M | 100M |
| Mar 06, 2024 |
Stock Split
8-K filing: Stock split 1-for-5 | Outstanding: 32,951,673 → 6,590,334 |
6.6M | 110M |
| Feb 08, 2024 |
8-K filing: China Pharma Holdings, Inc. subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Agreement with Lihua Li, acquiring an invention patent for a pharmaceutical composition for psoriasis treatment for $1.50 million, paid in common stock at $0.10 per share. ($1.5M proceeds) |
33M | 560M |
| Feb 06, 2024 |
S-3/A filing: China Pharma Holdings, Inc. may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants, rights or units up to an aggregate offering price not exceeding $50,000,000. |
33M | 560M |
| Jan 12, 2024 |
S-3 filing: China Pharma Holdings, Inc. may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities (which may be convertible into or exchangeable for common stock), warrants, rights or units that include any of these securities up to an aggregate offering price not exceeding $50,000,000. |
33M | 520M |
| Dec 21, 2023 |
8-K filing: China Pharma Holdings, Inc. entered into a Technology Transfer Agreement through its subsidiary Helpson with Tao Liu, where Helpson will acquire the Invention Patent for $1.65 million, payable in common stock at $0.11 per share. ($1.65M proceeds) |
33M | 0 |
| Nov 13, 2023 |
10-Q filing | 33.0M shares outstanding |
33M | 0 |
| Aug 14, 2023 |
10-Q filing | 11.4M shares outstanding |
11M | 2M |
| May 12, 2023 |
10-Q filing | 9.7M shares outstanding |
9.7M | 3.7M |
| Mar 30, 2023 |
10-K filing | 8.5M shares outstanding |
8.5M | 5M |
| Mar 06, 2023 |
Stock Split
8-K filing: Stock split 1-for-10 | Outstanding: 50,016,129 → 5,001,612 |
5M | 8.4M |
| Dec 02, 2022 |
8-K filing: China Pharma Holdings, Inc.'s subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd, entered into a Technology Transfer Contract with Chengdu Bonier Medical Technology Development Co., Ltd, acquiring the Utility Model Patent and Invention Patent application right in exchange for common stock valued at approximately $2.1 million. ($2.1M proceeds) |
50M | 84M |
| Nov 14, 2022 |
10-Q filing | 50.0M shares outstanding |
50M | 84M |
| Aug 11, 2022 |
10-Q filing | 48.5M shares outstanding |
48M | 86M |
| May 12, 2022 |
10-Q filing | 47.4M shares outstanding |
47M | 87M |
| Mar 30, 2022 |
10-K filing | 47.3M shares outstanding |
47M | 87M |
| Nov 23, 2021 |
8-K filing: China Pharma Holdings, Inc. entered into a Securities Purchase Agreement with Streeterville Capital, LLC, issuing an unsecured convertible promissory note with an original principal amount of $5,250,000 in exchange for $5,000,000, reflecting an original issue discount of $250,000, with the transaction closing on November 19, 2021. ($5.0M proceeds) |
47M | 87M |
| Nov 12, 2021 |
10-Q filing | 47.3M shares outstanding |
47M | 87M |
| Aug 13, 2021 |
10-Q filing | 43.6M shares outstanding |
44M | 91M |
| May 14, 2021 |
10-Q filing | 43.6M shares outstanding |
44M | 91M |
| Mar 26, 2021 |
10-K filing | 45.6M shares outstanding |
46M | 89M |
| Jan 08, 2021 |
S-3 filing: China Pharma Holdings, Inc. may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities (which may be convertible into or exchangeable for common stock), warrants, rights or units that include any of these securities having an aggregate initial offering price not exceeding $50,000,000. |
44M | 91M |
| Nov 13, 2020 |
10-Q filing | 43.6M shares outstanding |
44M | 0 |
| Aug 13, 2020 |
10-Q filing | 43.6M shares outstanding |
44M | 0 |
| May 14, 2020 |
10-Q filing | 43.6M shares outstanding |
44M | 0 |
| Mar 30, 2020 |
10-K filing | 43.6M shares outstanding |
44M | 0 |